Broadcasting the latest developments in GU cancer
Brian and Tom tag team moderate this session which covers combination data, VEGF/PD1 bispecifics, microbiome approaches, cellular therapy and enrichment strategies.
Tom leads the panel discussion about this evolving space including the RAMPART data and the press release about pembro/belzu.
Brian moderates a panel of Chris Sweeney, Tanya Dorff, Mike Morris, Neeraj Aggarwal and Chuck Ryan as they discus and debate the mHSPC space with many treatment options.
Brian leads a discussion of Rana McCay, Chris Sweeney and Michael Morris on the PSMAddition data and the landscape of radioligands in prostate cancer.
Brian takes the role of the FDA and we conduct a mock ODAC on the CREST and POTOMAC data
Hay vida más allá de EV Pembro. Los Dres Durán, Gómez de Liaño y Coca Membribes repasan el estudio de DV-Toripalimab presentado recientemente en ESMO. Más similitudes que diferencias con EV302 aunque quedan algunas preguntas por responder. Necesitamos más ensayos para entender cuándo hay que interrumpir el tratamiento, así como un mayor seguimiento de los pacientes. También repasaremos el arsenal de nuevos ADCs en marcha que seguirán aportando evidencia en esta población.
Los Dres Duran, Gómez de Liaño y Coca Membribes repasan el escenario perioperatorio en cáncer de vejiga músculo infiltrante. En cisplatino ineldgibles, KN905 es un ensayo transformativo en esta población única que hasta ahora había quedado apartada de los ensayos, y para los que no existía ningún tratamiento efectivo más allá de la cirugía. El rol de ctDNA es clave para entender cuál será el futuro respecto a la cirugía.
IMvigor011試験など最新の臨床データをもとに、ctDNAを用いた周術期治療戦略についての最前線をエキスパートが語ります
ADCが転移性膀胱がん治療にもたらすインパクトをテーマに、RC48-C16試験など最新エビデンスをJun Guo先生をはじめ、世界のエキスパートたちが語ります。
Brian takes the role of FDA and critically appraises the data. Then Tom (CREST) and Jonathan Rosenberg (POTOMAC) defend the data on behalf of each Sponsor. Our expert panel then asks tough questions and votes for or against approval.
Tom moderates Jun Guo, Matt Galsky, Michiel Van der Heidjen and Shilpa Gupta as they discuss this ever-expanding class of agents in bladder cancer.
The first session from UromigosLive 2025! In this episode, Tom moderates as Jonathan Rosenberg, Matt Galsky, Kala Sridhar and Josh Meeks discuss the peri-operative space and the impact of the neoadjuvant EVP and other data.
Tom and Brian discuss the bladder cancer highlights from ESMO 2025. Show throwing is discussed.
Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025
Alex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA
Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.
Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC
Elena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025
Paul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE
Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!
James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC
Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study
Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.
Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025
Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin
Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer
Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer
Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate cancer.
Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.
Erdafitinibがついに承認されましたが、依然として多くのCQが残されています。日常診療に役立つ最新のデータをもとに、その活用法についてディスカッションしました。
We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.
The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.
Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.
5月に改訂されたASCOのmCRPC薬物療法のガイドラインについて3人でディスカッションしました！！評価はいかに？
Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.
Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.
Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.
Brian, Tom and Silke discuss their highlights form ASCO 2025
Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.
Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025
Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone
Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.
Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.
Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.
Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation
Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.
David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.
Practice Changing? 独断と偏見で選んだ注目演題について結果の予想も含めて議論しました。
Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025
© 2020-2025 Ivy Podcast Discovery LLC
